Table 3. RECIST response in evaluable patients.
HCQ dose cohort | N | PR | SD | PD | NE |
---|---|---|---|---|---|
Phase I dose escalation | |||||
200 | 6 | 0 | 4 | 2 | 5 |
400 | 3 | 0 | 3 | 0 | 0 |
800 | 9 | 0 | 5 | 4 | 0 |
1200 | 3 | 0 | 2 | 1 | 0 |
Total | 21 | 0 (0%) | 14 (67%) | 7 (33%) | 5 |
Melanoma patients | |||||
200–800 | 6 | 0 | 5 | 1 | 2 |
1200 | 13 | 0 | 9 | 4 | 1 |
Total | 19 | 0 | 14 (74%) | 5 (26%) | 3 |
PR, Partial response; SD, stable disease; PD, progressive disease; NE, not evaluable